The follow-up evaluation method of the implementation of WHO “Access to Essential Medicines” resolution: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

LIN Mao ^1,2,3,4 ^# , JIANG Lucan ^1,2,3,4 ^# , ZENG Linan ^1,2,3 , ZHANG Yang ^1,2,3 , GUI Ge ^1,2,3,4 ,  ZHANG Lingli ^1,2,3

1. Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R.China;
2. Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R.China;
3. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, 610041, P.R.China;
4. West China School of Pharmacy, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding author：

ZHANG Lingli, Email: zhanglingli@scu.edu.cn

Keywords：

World health organization; World health assembly; Resolution; Essential medicine; Accessibility; Assessment method; Indicator

DOI：

10.7507/1672-2531.201810085

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To construct a follow-up evaluation indicator system on the implementation of the WHO resolution of " Access to essential medicines” by systematic review, and to provide a methodological support for tracking the implementation of the resolution, with a view to providing evidence of decision-making to promote the accessibility of essential medicines and further promote and improve the national essential medicine policy. It also provides a methodological reference for investigating the implementation of other public health sector resolutions.Methods PubMed, EMbase, The Cochrane Library, Web of Science, CBM, WanFang Data and CNKI databases and relevant international or national official websites of pharmaceutical administration department or academic organization were searched to collect studies on accessibility of WHO essential drugs from inception to February, 2016. Two researchers independently screened literature, extracted data, and qualitative analysis was used to sort out and screen the evaluation indicators for the implementation of the WHO resolution of "Access to essential medicines".Results A total of 60 relevant literatures, three guides and 19 progress reports of the World Health Assembly from official websites were included. Through the screening of indicators, we could get two parts: the indicators of measures to implement the resolution and the indicators of the results of the implementation of the resolution.Conclusions This study analyzes the implementation of the resolution of the health system in the progress report of the World Health Assembly 2013–2015, divides the implementation of the resolution into two parts: the implementation of the resolution and the results of the implementation of the resolution. An indicator system for establishing measures and evaluation the resolution has been found. Expert consultations will be further developed to establish the final indicators for the implementation of the "Access to essential medicines".

Citation： LIN Mao, JIANG Lucan, ZENG Linan, ZHANG Yang, GUI Ge, ZHANG Lingli. The follow-up evaluation method of the implementation of WHO “Access to Essential Medicines” resolution: a systematic review. Chinese Journal of Evidence-Based Medicine, 2019, 19(4): 471-480. doi: 10.7507/1672-2531.201810085 Copy

1.	World Health Organization. How to develop and implement a national drug policy (2 Edition). Available at: http://apps.who.int/medicinedocs/en/d/Js2283e/4.1.2.html.
2.	World Health Organization. Health topic: essential medicines. Available at: http://www.who.int/topics/essential_medicines/en/.
3.	World Health Organization. 2013-2020年预防和控制慢性非传染性疾病行动计划. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_9-ch.pdf.
4.	World Health Organization. Improving access to essential medicines in the Western Pacific region. Available at: http://www.wpro.who.int/NR/rdonlyres/588F3CB4-22F9-4543-A65E-BB447D8425AA/0/Regional_Strategy_for_Improving_Access.pdf.
5.	World Health Assembly. Access to essential medicine (WHA 67.22). Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA67-REC1/A67_2014_REC1-ch.pdf#page=25.
6.	Anson A, Ramay B, de Esparza AR, et al. Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health, 2012, 8(1): 22-31.
7.	Babar ZU, Ibrahim MI, Singh H, et al. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med, 2007, 4(3): e82.
8.	Babar ZU, Lessing C, Mace C, et al. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries. Pharmacoeconomics, 2013, 31(11): 1063-1082.
9.	Balasubramaniam R, Benaragama BV, Sri Ranganathan S. A national survey of price and affordability of key essential medicines for children in Sri Lanka. Indian J Pediatr, 2014, 81(4): 362-367.
10.	Andréa DB, Helfer AP, Camargo AL, et al. Is the Brazilian pharmaceutical policy ensuring population access to essential medicines? Global Health, 2012, 8(1): 6-16.
11.	Jiang M, Zhou Z, Wu L, et al. Medicine prices, availability, and affordability in the Shanxi province in China: implications for the future. Int J Clin Pharm, 2015, 37(1): 12-17.
12.	Cameron A, Bansal A, Dua T, et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia, 2012, 53(6): 962-969.
13.	Kotwani A, Ewen M, Dey D, et al. Prices & availability of common medicines at six sites in India using a standard methodology. Indian J Med Res, 2007, 125(5): 645-654.
14.	Kotwani A. Availability, price and affordability of asthma medicines in five Indian states. Int J Tuberc Lung Dis, 2009, 13(5): 574-579.
15.	Chahal HS, St Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. J Glob Health, 2013, 3(2): 020405.
16.	Mhlanga BS, Suleman F. Price, availability and affordability of medicines. Afr J Prim Health Care Fam Med, 2014, 6(1): E1-E6.
17.	Cheraghali AM, Idries AM. Availability, affordability, and prescribing pattern of medicines in Sudan. Pharm World Sci, 2009, 31(2): 209-215.
18.	Wang X, Fang Y, Yang S, et al. Access to paediatric essential medicines: a survey of prices, availability, affordability and price components in Shaanxi Province, China. PLoS One, 2014, 9(3): e90365.
19.	Dabare PRL, Wanigatunge CA, Beneragama BH. A national survey on availability, price and affordability of selected essential medicines for noncommunicable diseases in Sri Lanka. BMC Public Health, 2014, 14: 817-827.
20.	Senarathna SM, Mannapperuma U, Fernandopulle BM. Medicine prices, availability and affordability in Sri Lanka. Indian J Pharmacol, 2011, 43(1): 60-63.
21.	Carasso BS, Lagarde M, Tesfaye A, et al. Availability of essential medicines in Ethiopia: an efficiency-equity trade-off? Trop Med Int Health, 2009, 14(11): 1394-1400.
22.	陈高洁, 席晓宇, 褚淑贞. 基于药师的角度对基本药物可及性情况的KAP调查. 中国药事, 2011, 25(8): 755-757.
23.	陈瑶, 代涛, 白冰. 安徽省基本药物可及性实证研究. 北京: 中国医学科学院/北京协和医学院医学信息研究所/图书馆学术年会, 2013.
24.	陈瑶, 白冰, 代涛. 安徽省基层医疗卫生机构基本药物制度实施效果. 中国卫生政策研究, 2013, 6(4): 31-35.
25.	代涛, 黄红霞, 梅遂章, 等. 河南省基层医疗卫生机构基本药物制度实施效果. 中国卫生政策研究, 2013, 6(4): 36-40.
26.	代涛, 白冰, 陈瑶. 基本药物制度实施效果评价研究综述. 中国卫生政策研究, 2013, 6(4): 12-18.
27.	管晓东, 信枭雄, 刘洋, 等. 我国基本药物可负担性评价实证研究. 中国药房, 2013, (24): 2220-2224.
28.	管晓东, 李晗, 刘洋, 等. 我国基本药物价格水平实证研究. 中国药房, 2013, (24): 2224-2228.
29.	杨肖光, 朱晓丽, 代涛. 北京市昌平区社区卫生服务中心基本药物制度实施效果的评价. 首都食品与医药, 2015, (16): 13-15.
30.	虎翼. 宁夏基本药物可及度指标性评价研究. 银川: 宁夏医科大学, 2014.
31.	黄勇. 基于患者角度的我国基本药物行为可及性研究. 中国医药指南, 2013, (22): 721-723.
32.	姜明欢, 方宇, 王文娟, 等. 陕西省公立医院和零售药店基本药物价格及可获得性比较研究. 2012年中国药学会药事管理专业委员会年会暨" 十二五”医药科学发展学术研讨会论文集(下册), 2012.
33.	姜明欢, 周忠良, 方宇, 等. 陕西省零售药店药品价格与可获得性评估研究. 中国卫生政策研究, 2013, 6(8): 37-42.
34.	姜明欢, 王乐, 王文娟, 等. 陕西省公立医院基本药物制度实施状况评估. 中华医院管理杂志, 2013, 29(5): 347-352.
35.	李锋. 广州市社区卫生服务机构基本药物可获得性调查. 中国卫生经济, 2011, 30(8): 52-54.
36.	李萍, 阳昊, 张新平. 湖北省农村医疗机构和零售药店基本药物价格调查. 医学与社会, 2010, 23(10): 51-53.
37.	李萍, 吕景睿, 阳昊, 等. 湖北省农村居民基本药物可负担性研究. 医学与社会, 2010, 23(2): 18-20.
38.	李显文, 章燕丽, 吴森林, 等. 实施基本药物制度后基层的药品可及性调查. 卫生经济研究, 2012, (6): 24-26.
39.	李显文, 章燕丽, 吴森林. 基本药物制度下药品费用可负担性实证分析. 中国农村卫生事业管理, 2013, 33(1): 10-13.
40.	林腾飞, 胡明, 吴佳怡. 四川省农村基层医疗机构基本药物制度实施效果研究. 中国卫生政策研究, 2013, 6(10): 48-53.
41.	刘慧, 张晓萌. 宣教干预对基本药物心理可及性的影响调查. 赤峰学院学报(自然科学版), 2014, (8): 49-50.
42.	马金华, 席晓宇, 褚淑贞. 基于患者的角度对基本药物可及性情况的知识-态度-行为调查分析. 中国新药杂志, 2012, (18): 2109-2112.
43.	宋燕, 卞鹰. 浙江省基层医疗机构基本药物制度实施效果的综合评价. 中国卫生政策研究, 2011, 4(10): 43-47.
44.	宋燕, 卞鹰. 基本药物制度对提高中国农村地区药品可及性的实证分析. 北京: 中国卫生政策研究论坛, 2012.
45.	唐绍贵, 侯天宇, 赵茜, 等. 山西省某县级医疗卫生机构基本药物价格水平与可负担性研究. 中国药房, 2014, (24): 2223-2226.
46.	王芳, 丁雪, 代涛. 重庆市基层医疗卫生机构基本药物制度实施效果. 中国卫生政策研究, 2013, 6(4): 41-46.
47.	王力, 孙希望, 余苏珍, 等. 江西省农村居民基本药物可及性调查与分析. 中国卫生经济, 2012, 31(12): 62-63.
48.	王力, 余苏珍, 陈和利, 等. 江西省农村地区基本药物可获得性情况分析. 卫生经济研究, 2013, (2): 30-31.
49.	王潇, 杨世民, 方宇, 等. 基于WHO/HAI标准化法的陕西省零售药店儿童基本药物价格及供应研究. 2013年中国药学会药事管理专业委员会年会暨" 医药安全与科学发展”学术论坛论文集(下册), 2013.
50.	刘璐, 方宇, 姜明欢, 等. 西安市县级公立医院实行药品零差率的补偿机制研究. 中国药业, 2013, 22(12): 1-2.
51.	魏艳, 尹文强, 范海平, 等. 基于熵权灰色关联法的乡镇卫生院基本药物可获得性研究. 中国卫生经济, 2014, 33(8): 70-72.
52.	吴红雁, 潘岚岚, 陈磊. WHO/HAI标准调查法对部分国家与地区基本药物的可获得性研究. 中国药房, 2015, (9): 1153-1156.
53.	席晓宇, 马金华, 褚淑贞. 基于医务工作者的基本药物可及性KAP调查. 药品评价, 2011, 8(12): 16-20.
54.	席晓宇, 徐丹妮. 基于文献研究视角的基本药物可及性问题研究. 药品评价, 2012, 9(8): 6-12.
55.	徐伟, 殷丹妮. 江苏省基本药物可负担性实证研究. 上海医药, 2012, 33(3): 43-47.
56.	徐伟, 殷丹妮. 我国基本药物可负担性实证研究. 中国药房, 2012, (40): 3745-3747.
57.	徐伟, 李静. 江苏省基本药物可获得性实证研究. 中国药房, 2013, (8): 676-679.
58.	阳昊, 李萍, 张新平. 湖北省孝感市农村地区基本药物可获得性研究. 中国药房, 2008, 19(29): 2244-2247.
59.	阳昊. 湖北省农村地区县乡两级基本药物可获得性研究. 武汉: 华中科技大学, 2009.
60.	杨慧云. 山东省农村地区基本药物的可及性研究. 济南: 山东大学, 2012.
61.	杨显辉. 我国基本药物制度评估指标体系研究. 郑州: 河南大学, 2012.
62.	叶露, 胡善联, Margaret E, et al. 上海市基本药物可负担性实证研究. 中国卫生资源, 2008, 11(4): 195-196.
63.	张新平, 郑双江, 田昕. 社区卫生服务机构基本药物可获得性研究. 中国卫生政策研究, 2010, 3(6): 14-17.
64.	张莹芳, 常育. 我国西部地区部分省市的基本药物可负担性实证研究. 中国医药指南, 2013, (3): 676-677.
65.	张悦, 罗加详, 虎翼, 等. 宁夏基本药物可及性评价指标体系的建立. 卫生软科学, 2015, (1): 1-4.
66.	World Health Organization. Indicators for monitoring national drug policies (2nd Edition). Available at: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=93&codcch=2066.
67.	World Health Organization/Health Action International. Measuring medicine prices, availability, affordability and price components (2nd Edition). Available at: http://www.who.int/medicines/areas/access/medicines_prices08/en/index.html.
68.	World Health Organization. How to investigate drug use in health facilities. Available at: http://apps.who.int/medicinedocs/en/d/Js2289e/.
69.	World Health Organization. Fifty-sixth world health assembly-WHO medicines strategy: progress report. Available at: http://apps.who.int/gb/archive/pdf_files/WHA56/ea5616.pdf.
70.	World Health Organization. Fifty-Seventh World Health Assembly-Implementation of resolutions (progress reports). Available at: http://apps.who.int/gb/archive/pdf_files/WHA57/A57_18-en.pdf.
71.	World Health Organization. Fifty-Seventh World Health Assembly-Road safety and health: update. Available at: http://apps.who.int/gb/archive/pdf_files/WHA57/A57_10Add1-en.pdf.
72.	World Health Organization. Fifty-Eighth World Health Assembly-International Plan of Action on Ageing: report on implementation. Available at: http://apps.who.int/gb/archive/pdf_files/WHA58/A58_19-en.pdf.
73.	World Health Organization. Fifty-Eighth World Health Assembly-Implementation of resolutions (progress reports) WHO Framework Convention on Tobacco Control. Available at: http://apps.who.int/gb/archive/pdf_files/WHA58/A58_23Add1-en.pdf.
74.	World Health Organization. Fifty-Eighth World Health Assembly-Implementation of resolutions (progress reports). Available at: http://apps.who.int/gb/archive/pdf_files/WHA58/A58_23-en.pdf.
75.	World Health Organization. Fifty-Ninth World Health Assembly-Implementation of resolutions (progress reports). Available at: http://apps.who.int/gb/archive/pdf_files/WHA59/A59_23-en.pdf.
76.	World Health Organization. Fifty-Ninth World Health Assembly-Health conditions in the occupied Palestinian territory, including east Jerusalem, and in the occupied Syrian Golan: progress report. Available at: http://apps.who.int/gb/archive/pdf_files/WHA59/A59_24-en.pdf.
77.	World Health Organization. Sixtieth World Health Assembly-Progress reports on technical and health matters. Available at: http://apps.who.int/gb/archive/pdf_files/WHA60/A60_28-en.pdf.
78.	World Health Organization. Sixty-First World Health Assembly- Progress reports on technical and health matters. Available at: http://apps.who.int/gb/archive/pdf_files/A61/A61_17-en.pdf.
79.	World Health Organization. Sixty-First World Health Assembly- Progress reports on technical and health matters. Available at: http://apps.who.int/gb/archive/pdf_files/A61/A61_17Add1-en.pdf.
80.	World Health Organization. Sixty-Second World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/A62/A62_23-en.pdf.
81.	World Health Organization. Sixty-Third World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_27-en.pdf.
82.	World Health Organization. Sixty-Fourth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_26-en.pdf.
83.	World Health Organization. Sixty-Fifth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_26-en.pdf.
84.	World Health Organization. Sixty-Sixth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_27Add1-en.pdf.
85.	World Health Organization. Sixty-Sixth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_27-en.pdf.
86.	World Health Organization. Sixty-Seventh World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_40-en.pdf.
87.	World Health Organization. Sixty-Eighth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_36-en.pdf.
88.	World Health Assembly. WHO medicines strategy. Available at: http://apps.who.int/gb/archive/pdf_files/WHA54/ea54r11.pdf. 99, 104, 105, 111, 112, 116-118.
89.	World Health Assembly. Social determinants of health: outcome of the World Conference on Social Determinants of Health. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_16-en.pdf.
90.	World Health Assembly. Availability, safety and quality of blood products. Available at: http://apps.who.int/gb/e/e_wha63.html.
91.	World Health Assembly. Human organ and tissue transplantation. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_24-en.pdf.
92.	World Health Assembly. Report of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property. Available at: https://www.who.int/mediacentre/events/2008/wha61/issues_paper1/en/.
93.	World Health Assembly. Quality of care: patient safety. Available at: http://apps.who.int/gb/archive/pdf_files/WHA55/ewha5518.pdf.
94.	World Health Assembly. Workers’ health: draft global plan of action. Available at: http://apps.who.int/gb/archive/pdf_files/WHA60/A60_20-en.pdf.
95.	World Health Assembly. Integrating gender analysis and actions into the work of WHO: draft strategy. Available at: http://apps.who.int/gb/archive/pdf_files/WHA60/A60_19-en.pdf.
96.	World Health Assembly. Progress in the rational use of medicines. Available at: http://apps.who.int/gb/archive/pdf_files/WHA60/A60_24-en.pdf.
97.	中华人民共和国卫生部等九部委. 关于建立国家基本药物制度的实施意见. Available at: http://www.sda.gov.cn/WS01/CL0056/40753.html.

1. World Health Organization. How to develop and implement a national drug policy (2 Edition). Available at: http://apps.who.int/medicinedocs/en/d/Js2283e/4.1.2.html.
2. World Health Organization. Health topic: essential medicines. Available at: http://www.who.int/topics/essential_medicines/en/.
3. World Health Organization. 2013-2020年预防和控制慢性非传染性疾病行动计划. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_9-ch.pdf.
4. World Health Organization. Improving access to essential medicines in the Western Pacific region. Available at: http://www.wpro.who.int/NR/rdonlyres/588F3CB4-22F9-4543-A65E-BB447D8425AA/0/Regional_Strategy_for_Improving_Access.pdf.
5. World Health Assembly. Access to essential medicine (WHA 67.22). Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA67-REC1/A67_2014_REC1-ch.pdf#page=25.
6. Anson A, Ramay B, de Esparza AR, et al. Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health, 2012, 8(1): 22-31.
7. Babar ZU, Ibrahim MI, Singh H, et al. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med, 2007, 4(3): e82.
8. Babar ZU, Lessing C, Mace C, et al. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries. Pharmacoeconomics, 2013, 31(11): 1063-1082.
9. Balasubramaniam R, Benaragama BV, Sri Ranganathan S. A national survey of price and affordability of key essential medicines for children in Sri Lanka. Indian J Pediatr, 2014, 81(4): 362-367.
10. Andréa DB, Helfer AP, Camargo AL, et al. Is the Brazilian pharmaceutical policy ensuring population access to essential medicines? Global Health, 2012, 8(1): 6-16.
11. Jiang M, Zhou Z, Wu L, et al. Medicine prices, availability, and affordability in the Shanxi province in China: implications for the future. Int J Clin Pharm, 2015, 37(1): 12-17.
12. Cameron A, Bansal A, Dua T, et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries. Epilepsia, 2012, 53(6): 962-969.
13. Kotwani A, Ewen M, Dey D, et al. Prices & availability of common medicines at six sites in India using a standard methodology. Indian J Med Res, 2007, 125(5): 645-654.
14. Kotwani A. Availability, price and affordability of asthma medicines in five Indian states. Int J Tuberc Lung Dis, 2009, 13(5): 574-579.
15. Chahal HS, St Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. J Glob Health, 2013, 3(2): 020405.
16. Mhlanga BS, Suleman F. Price, availability and affordability of medicines. Afr J Prim Health Care Fam Med, 2014, 6(1): E1-E6.
17. Cheraghali AM, Idries AM. Availability, affordability, and prescribing pattern of medicines in Sudan. Pharm World Sci, 2009, 31(2): 209-215.
18. Wang X, Fang Y, Yang S, et al. Access to paediatric essential medicines: a survey of prices, availability, affordability and price components in Shaanxi Province, China. PLoS One, 2014, 9(3): e90365.
19. Dabare PRL, Wanigatunge CA, Beneragama BH. A national survey on availability, price and affordability of selected essential medicines for noncommunicable diseases in Sri Lanka. BMC Public Health, 2014, 14: 817-827.
20. Senarathna SM, Mannapperuma U, Fernandopulle BM. Medicine prices, availability and affordability in Sri Lanka. Indian J Pharmacol, 2011, 43(1): 60-63.
21. Carasso BS, Lagarde M, Tesfaye A, et al. Availability of essential medicines in Ethiopia: an efficiency-equity trade-off? Trop Med Int Health, 2009, 14(11): 1394-1400.
22. 陈高洁, 席晓宇, 褚淑贞. 基于药师的角度对基本药物可及性情况的KAP调查. 中国药事, 2011, 25(8): 755-757.
23. 陈瑶, 代涛, 白冰. 安徽省基本药物可及性实证研究. 北京: 中国医学科学院/北京协和医学院医学信息研究所/图书馆学术年会, 2013.
24. 陈瑶, 白冰, 代涛. 安徽省基层医疗卫生机构基本药物制度实施效果. 中国卫生政策研究, 2013, 6(4): 31-35.
25. 代涛, 黄红霞, 梅遂章, 等. 河南省基层医疗卫生机构基本药物制度实施效果. 中国卫生政策研究, 2013, 6(4): 36-40.
26. 代涛, 白冰, 陈瑶. 基本药物制度实施效果评价研究综述. 中国卫生政策研究, 2013, 6(4): 12-18.
27. 管晓东, 信枭雄, 刘洋, 等. 我国基本药物可负担性评价实证研究. 中国药房, 2013, (24): 2220-2224.
28. 管晓东, 李晗, 刘洋, 等. 我国基本药物价格水平实证研究. 中国药房, 2013, (24): 2224-2228.
29. 杨肖光, 朱晓丽, 代涛. 北京市昌平区社区卫生服务中心基本药物制度实施效果的评价. 首都食品与医药, 2015, (16): 13-15.
30. 虎翼. 宁夏基本药物可及度指标性评价研究. 银川: 宁夏医科大学, 2014.
31. 黄勇. 基于患者角度的我国基本药物行为可及性研究. 中国医药指南, 2013, (22): 721-723.
32. 姜明欢, 方宇, 王文娟, 等. 陕西省公立医院和零售药店基本药物价格及可获得性比较研究. 2012年中国药学会药事管理专业委员会年会暨" 十二五”医药科学发展学术研讨会论文集(下册), 2012.
33. 姜明欢, 周忠良, 方宇, 等. 陕西省零售药店药品价格与可获得性评估研究. 中国卫生政策研究, 2013, 6(8): 37-42.
34. 姜明欢, 王乐, 王文娟, 等. 陕西省公立医院基本药物制度实施状况评估. 中华医院管理杂志, 2013, 29(5): 347-352.
35. 李锋. 广州市社区卫生服务机构基本药物可获得性调查. 中国卫生经济, 2011, 30(8): 52-54.
36. 李萍, 阳昊, 张新平. 湖北省农村医疗机构和零售药店基本药物价格调查. 医学与社会, 2010, 23(10): 51-53.
37. 李萍, 吕景睿, 阳昊, 等. 湖北省农村居民基本药物可负担性研究. 医学与社会, 2010, 23(2): 18-20.
38. 李显文, 章燕丽, 吴森林, 等. 实施基本药物制度后基层的药品可及性调查. 卫生经济研究, 2012, (6): 24-26.
39. 李显文, 章燕丽, 吴森林. 基本药物制度下药品费用可负担性实证分析. 中国农村卫生事业管理, 2013, 33(1): 10-13.
40. 林腾飞, 胡明, 吴佳怡. 四川省农村基层医疗机构基本药物制度实施效果研究. 中国卫生政策研究, 2013, 6(10): 48-53.
41. 刘慧, 张晓萌. 宣教干预对基本药物心理可及性的影响调查. 赤峰学院学报(自然科学版), 2014, (8): 49-50.
42. 马金华, 席晓宇, 褚淑贞. 基于患者的角度对基本药物可及性情况的知识-态度-行为调查分析. 中国新药杂志, 2012, (18): 2109-2112.
43. 宋燕, 卞鹰. 浙江省基层医疗机构基本药物制度实施效果的综合评价. 中国卫生政策研究, 2011, 4(10): 43-47.
44. 宋燕, 卞鹰. 基本药物制度对提高中国农村地区药品可及性的实证分析. 北京: 中国卫生政策研究论坛, 2012.
45. 唐绍贵, 侯天宇, 赵茜, 等. 山西省某县级医疗卫生机构基本药物价格水平与可负担性研究. 中国药房, 2014, (24): 2223-2226.
46. 王芳, 丁雪, 代涛. 重庆市基层医疗卫生机构基本药物制度实施效果. 中国卫生政策研究, 2013, 6(4): 41-46.
47. 王力, 孙希望, 余苏珍, 等. 江西省农村居民基本药物可及性调查与分析. 中国卫生经济, 2012, 31(12): 62-63.
48. 王力, 余苏珍, 陈和利, 等. 江西省农村地区基本药物可获得性情况分析. 卫生经济研究, 2013, (2): 30-31.
49. 王潇, 杨世民, 方宇, 等. 基于WHO/HAI标准化法的陕西省零售药店儿童基本药物价格及供应研究. 2013年中国药学会药事管理专业委员会年会暨" 医药安全与科学发展”学术论坛论文集(下册), 2013.
50. 刘璐, 方宇, 姜明欢, 等. 西安市县级公立医院实行药品零差率的补偿机制研究. 中国药业, 2013, 22(12): 1-2.
51. 魏艳, 尹文强, 范海平, 等. 基于熵权灰色关联法的乡镇卫生院基本药物可获得性研究. 中国卫生经济, 2014, 33(8): 70-72.
52. 吴红雁, 潘岚岚, 陈磊. WHO/HAI标准调查法对部分国家与地区基本药物的可获得性研究. 中国药房, 2015, (9): 1153-1156.
53. 席晓宇, 马金华, 褚淑贞. 基于医务工作者的基本药物可及性KAP调查. 药品评价, 2011, 8(12): 16-20.
54. 席晓宇, 徐丹妮. 基于文献研究视角的基本药物可及性问题研究. 药品评价, 2012, 9(8): 6-12.
55. 徐伟, 殷丹妮. 江苏省基本药物可负担性实证研究. 上海医药, 2012, 33(3): 43-47.
56. 徐伟, 殷丹妮. 我国基本药物可负担性实证研究. 中国药房, 2012, (40): 3745-3747.
57. 徐伟, 李静. 江苏省基本药物可获得性实证研究. 中国药房, 2013, (8): 676-679.
58. 阳昊, 李萍, 张新平. 湖北省孝感市农村地区基本药物可获得性研究. 中国药房, 2008, 19(29): 2244-2247.
59. 阳昊. 湖北省农村地区县乡两级基本药物可获得性研究. 武汉: 华中科技大学, 2009.
60. 杨慧云. 山东省农村地区基本药物的可及性研究. 济南: 山东大学, 2012.
61. 杨显辉. 我国基本药物制度评估指标体系研究. 郑州: 河南大学, 2012.
62. 叶露, 胡善联, Margaret E, et al. 上海市基本药物可负担性实证研究. 中国卫生资源, 2008, 11(4): 195-196.
63. 张新平, 郑双江, 田昕. 社区卫生服务机构基本药物可获得性研究. 中国卫生政策研究, 2010, 3(6): 14-17.
64. 张莹芳, 常育. 我国西部地区部分省市的基本药物可负担性实证研究. 中国医药指南, 2013, (3): 676-677.
65. 张悦, 罗加详, 虎翼, 等. 宁夏基本药物可及性评价指标体系的建立. 卫生软科学, 2015, (1): 1-4.
66. World Health Organization. Indicators for monitoring national drug policies (2nd Edition). Available at: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=93&codcch=2066.
67. World Health Organization/Health Action International. Measuring medicine prices, availability, affordability and price components (2nd Edition). Available at: http://www.who.int/medicines/areas/access/medicines_prices08/en/index.html.
68. World Health Organization. How to investigate drug use in health facilities. Available at: http://apps.who.int/medicinedocs/en/d/Js2289e/.
69. World Health Organization. Fifty-sixth world health assembly-WHO medicines strategy: progress report. Available at: http://apps.who.int/gb/archive/pdf_files/WHA56/ea5616.pdf.
70. World Health Organization. Fifty-Seventh World Health Assembly-Implementation of resolutions (progress reports). Available at: http://apps.who.int/gb/archive/pdf_files/WHA57/A57_18-en.pdf.
71. World Health Organization. Fifty-Seventh World Health Assembly-Road safety and health: update. Available at: http://apps.who.int/gb/archive/pdf_files/WHA57/A57_10Add1-en.pdf.
72. World Health Organization. Fifty-Eighth World Health Assembly-International Plan of Action on Ageing: report on implementation. Available at: http://apps.who.int/gb/archive/pdf_files/WHA58/A58_19-en.pdf.
73. World Health Organization. Fifty-Eighth World Health Assembly-Implementation of resolutions (progress reports) WHO Framework Convention on Tobacco Control. Available at: http://apps.who.int/gb/archive/pdf_files/WHA58/A58_23Add1-en.pdf.
74. World Health Organization. Fifty-Eighth World Health Assembly-Implementation of resolutions (progress reports). Available at: http://apps.who.int/gb/archive/pdf_files/WHA58/A58_23-en.pdf.
75. World Health Organization. Fifty-Ninth World Health Assembly-Implementation of resolutions (progress reports). Available at: http://apps.who.int/gb/archive/pdf_files/WHA59/A59_23-en.pdf.
76. World Health Organization. Fifty-Ninth World Health Assembly-Health conditions in the occupied Palestinian territory, including east Jerusalem, and in the occupied Syrian Golan: progress report. Available at: http://apps.who.int/gb/archive/pdf_files/WHA59/A59_24-en.pdf.
77. World Health Organization. Sixtieth World Health Assembly-Progress reports on technical and health matters. Available at: http://apps.who.int/gb/archive/pdf_files/WHA60/A60_28-en.pdf.
78. World Health Organization. Sixty-First World Health Assembly- Progress reports on technical and health matters. Available at: http://apps.who.int/gb/archive/pdf_files/A61/A61_17-en.pdf.
79. World Health Organization. Sixty-First World Health Assembly- Progress reports on technical and health matters. Available at: http://apps.who.int/gb/archive/pdf_files/A61/A61_17Add1-en.pdf.
80. World Health Organization. Sixty-Second World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/A62/A62_23-en.pdf.
81. World Health Organization. Sixty-Third World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_27-en.pdf.
82. World Health Organization. Sixty-Fourth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_26-en.pdf.
83. World Health Organization. Sixty-Fifth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_26-en.pdf.
84. World Health Organization. Sixty-Sixth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_27Add1-en.pdf.
85. World Health Organization. Sixty-Sixth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_27-en.pdf.
86. World Health Organization. Sixty-Seventh World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_40-en.pdf.
87. World Health Organization. Sixty-Eighth World Health Assembly-Progress reports. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_36-en.pdf.
88. World Health Assembly. WHO medicines strategy. Available at: http://apps.who.int/gb/archive/pdf_files/WHA54/ea54r11.pdf. 99, 104, 105, 111, 112, 116-118.
89. World Health Assembly. Social determinants of health: outcome of the World Conference on Social Determinants of Health. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_16-en.pdf.
90. World Health Assembly. Availability, safety and quality of blood products. Available at: http://apps.who.int/gb/e/e_wha63.html.
91. World Health Assembly. Human organ and tissue transplantation. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_24-en.pdf.
92. World Health Assembly. Report of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property. Available at: https://www.who.int/mediacentre/events/2008/wha61/issues_paper1/en/.
93. World Health Assembly. Quality of care: patient safety. Available at: http://apps.who.int/gb/archive/pdf_files/WHA55/ewha5518.pdf.
94. World Health Assembly. Workers’ health: draft global plan of action. Available at: http://apps.who.int/gb/archive/pdf_files/WHA60/A60_20-en.pdf.
95. World Health Assembly. Integrating gender analysis and actions into the work of WHO: draft strategy. Available at: http://apps.who.int/gb/archive/pdf_files/WHA60/A60_19-en.pdf.
96. World Health Assembly. Progress in the rational use of medicines. Available at: http://apps.who.int/gb/archive/pdf_files/WHA60/A60_24-en.pdf.
97. 中华人民共和国卫生部等九部委. 关于建立国家基本药物制度的实施意见. Available at: http://www.sda.gov.cn/WS01/CL0056/40753.html.

Chinese Journal of Evidence-Based Medicine

The follow-up evaluation method of the implementation of WHO “Access to Essential Medicines” resolution: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content